human
coronavirus
hcov
larg
envelop
rna
virus
coronavirida
famili
caus
common
cold
ill
seriou
acut
respiratori
ill
ri
includ
pneumonia
exacerb
underli
lung
diseas
croup
bronchiol
alphacoronaviru
genu
lineag
along
pathogen
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
lineag
b
betacoronaviru
genu
outbreak
wuhan
china
novel
coronaviru
appear
betacoronaviru
made
studi
hcov
infect
import
report
infect
associ
morbid
mortal
involv
viru
public
health
concern
understand
immun
respons
hcov
import
design
possibl
protect
vaccin
novel
hcov
may
abl
use
human
enzym
cell
receptor
viral
cell
entri
strain
although
bind
heparan
sulfat
also
requir
viral
attach
infect
target
cell
concern
addit
neutral
antibodi
could
also
enhanc
infect
littl
known
point
antigen
novel
hcov
strain
human
innat
adapt
immun
respons
infect
provid
protect
reinfect
whether
cytokin
induct
may
enhanc
pathogen
sever
ill
antibodi
may
among
viral
strain
least
within
hcov
genu
due
conserv
viral
antigen
epitop
may
includ
neutral
function
induc
repeat
infect
earlier
life
henc
serolog
reactiv
common
hcov
strain
may
differ
among
chronic
ill
older
adult
compar
younger
adult
previou
studi
older
adult
underli
chronic
pulmonari
diseas
report
serum
immunoglobulin
g
igg
antibodi
four
hcov
strain
preval
studi
subject
mucos
immunoglobulin
antibodi
four
common
hcov
strain
nasal
wash
specimen
detect
minor
patient
mucos
immun
respons
also
deserv
studi
respect
mitig
hcov
infect
although
strain
may
target
infect
lower
respiratori
tree
due
purport
receptor
usag
neutral
antibodi
direct
hcov
spike
protein
may
protect
nonfunct
bind
antibodi
direct
viral
protein
report
assess
whether
neutral
antibodi
hcov
strain
present
increas
acut
ri
chosen
studi
associ
increas
bind
antibodi
hcov
strain
detect
hcov
viral
nucleic
acid
respiratori
secret
assess
correl
serum
bind
neutral
antibodi
compar
antibodi
respons
older
chronic
ill
adult
healthi
young
adult
prospect
observ
studi
conduct
novemb
juli
assess
ri
patient
age
year
underli
chronic
lung
heart
diseas
group
total
n
subject
ri
assess
overal
healthi
young
adult
age
year
group
total
n
ri
assess
overal
enrol
subject
particip
year
receiv
phone
call
everi
week
remind
contact
studi
personnel
time
onset
acut
ri
evalu
studi
physician
nurs
clinic
either
three
symptom
acut
ri
fever
bodi
temperatur
accompani
two
symptom
acut
ri
describ
sera
obtain
studi
enrol
subject
subsequ
ri
within
day
onset
time
acut
week
later
convalesc
respiratori
secret
collect
nasal
oropharyng
swab
within
day
onset
acut
ri
test
nucleic
acid
hcov
strain
respiratori
virus
multiplex
use
xtag
respiratori
viral
panel
fast
luminex
molecular
diagnost
inc
toronto
ontario
canada
studi
approv
respons
institut
review
board
saint
loui
univers
veteran
affair
va
st
loui
health
care
system
perform
complianc
relev
law
institut
guidelin
accord
ethic
standard
declar
helsinki
written
inform
consent
obtain
studi
subject
antigen
use
detect
bind
antibodi
immunosorb
assay
elisa
prepar
viru
grown
cell
respect
american
type
cultur
collect
atcc
manassa
va
atcc
gift
lia
van
der
hoek
univers
amsterdam
mock
antigen
prepar
uninfect
cell
cell
frozen
thaw
three
time
supernat
fluid
clarifi
cell
debri
centrifug
viru
concentr
overnight
centrifug
viru
pellet
resuspend
salin
concentr
viru
inactiv
psoralen
compound
sigma
st
loui
mo
follow
irradi
uv
light
describ
method
viral
inactiv
affect
viral
antigen
mock
antigen
prepar
way
uninfect
cell
grown
use
standard
tissu
cultur
techniqu
recombin
nucleoprotein
n
mock
antigen
produc
plasmid
dna
vector
without
n
protein
gene
use
antigen
detect
antibodi
describ
viral
mock
antigen
stock
throughout
assay
use
coat
maxisorp
immunopl
intern
rochest
ny
follow
sequenc
serum
serial
dilut
mous
igg
conjug
horseradish
peroxidas
accur
chemic
scientif
westburi
ny
peroxidas
substrat
kpl
gaithersburg
md
optic
densiti
measur
nm
spectrophotomet
serum
antibodi
titer
calcul
method
describ
posit
neg
control
sera
assay
confirm
consist
assay
also
sera
subject
evalu
assay
avoid
variabl
neutral
antibodi
assay
assess
percentag
cell
kill
hcov
colorimetr
bioassay
base
abil
live
cell
reduc
yellow
tetrazolium
salt
tetrazolium
bromid
mtt
st
loui
mo
blue
formazan
deriv
describ
sera
serial
dilut
incub
equal
volum
hcov
predetermin
stock
viru
dilut
kill
cell
gener
tissu
cultur
infecti
dose
per
unit
volum
transfer
plate
contain
monolay
appropri
tissu
cultur
cell
support
growth
hcov
viru
strain
control
infect
cell
exhibit
cytopath
effect
mtt
ad
absorb
nm
formazan
produc
live
cell
measur
spectrophotometr
titrat
curv
plot
percentag
cell
surviv
rel
control
surviv
vs
reciproc
serum
dilut
plot
analyz
use
nonlinear
regress
graphpad
softwar
prism
version
san
diego
ca
determin
serum
dilut
requir
protect
cell
cytotox
effect
hcov
viru
stock
use
throughout
assay
posit
neg
control
sera
assay
assur
reproduc
also
sera
subject
evalu
assay
avoid
variabl
descript
statist
fisher
exact
test
nonparametr
statist
test
use
compar
proport
continu
variabl
spearman
test
assess
correl
statist
analysi
done
use
statistica
releas
softwar
statsoft
inc
tulsa
ok
geometr
mean
bind
antibodi
titer
gmt
elisa
studi
enrol
sera
higher
entir
group
compar
group
subject
group
n
vs
group
n
vs
p
vs
p
ns
vs
p
ns
vs
p
ns
ri
assess
group
ri
assess
group
subject
ill
associ
hcov
infect
serolog
chang
pcr
posit
hcov
common
respiratori
viru
associ
ri
parent
studi
enterorhinoviru
detect
polymeras
chain
reaction
describ
sera
bracket
ri
focu
studi
follow
analys
like
provid
inform
util
measur
bind
neutral
antibodi
four
common
strain
hcov
ill
occur
older
adult
group
mean
age
year
min
max
year
younger
adult
group
mean
age
year
min
max
year
total
ri
threefold
increas
bind
antibodi
one
hcov
strain
compar
acut
convalesc
serum
antibodi
titer
includ
ri
threefold
increas
two
three
strain
one
ri
respiratori
secret
increas
bind
antibodi
ri
threefold
increas
bind
antibodi
titer
includ
nine
ill
three
group
six
group
three
five
group
group
eight
group
nine
group
eight
six
group
group
eight
ri
group
ri
group
increas
bind
antibodi
one
hcov
p
ns
neutral
antibodi
detect
two
acut
ri
sera
two
group
subject
detect
neutral
activ
ri
six
group
five
group
rise
neutral
antibodi
titer
six
two
group
four
group
four
one
group
three
group
four
ri
accompani
rise
neutral
antibodi
one
also
increas
therefor
total
number
ri
rise
neutral
antibodi
titer
one
hcov
strain
group
group
threefold
increas
elisa
antibodi
titer
predictor
minor
ill
increas
neutral
antibodi
hcov
tabl
total
ri
ri
threefold
less
fourfold
increas
bind
antibodi
increas
neutral
antibodi
titer
one
hcov
strain
p
ns
seven
ri
hcov
nucleic
acid
detect
respiratori
secret
one
group
one
group
three
group
two
group
six
seven
accompani
threefold
increas
bind
antibodi
four
increas
one
hcov
strain
bind
neutral
antibodi
acut
ill
sera
four
hcov
strain
three
rise
neutral
antibodi
one
ri
group
one
group
nucleic
acid
posit
increas
neutral
antibodi
one
ri
group
nucleic
acid
posit
inexplic
accompani
increas
neutral
antibodi
fourfold
rise
bind
antibodi
consid
acut
convalesc
sera
ri
gmt
higher
group
group
subject
bind
antibodi
neutral
antibodi
figur
acut
ill
sera
gmt
bind
antibodi
higher
group
group
convalesc
sera
gmt
bind
antibodi
neutral
antibodi
higher
group
group
subject
figur
group
subject
acut
ill
bind
antibodi
titer
posit
correl
r
p
convalesc
serum
titer
correl
bind
neutral
antibodi
r
p
r
p
bind
antibodi
r
p
group
subject
acut
ill
serum
bind
antibodi
titer
correl
r
p
convalesc
serum
bind
antibodi
titer
correl
r
p
bind
neutral
antibodi
r
p
group
subject
combin
convalesc
serum
bind
neutral
antibodi
titer
correl
r
p
also
separ
r
p
bind
antibodi
correl
r
p
reinfect
coronavirus
reportedli
common
despit
presenc
humor
immun
respons
except
one
subject
one
ri
associ
hcov
infect
per
subject
studi
lack
repeat
hcov
infect
may
influenc
ri
per
subject
meet
elig
criteria
assess
studi
known
often
clinic
signific
natur
exposur
hcov
might
occur
caus
risk
infect
sinc
preexist
serum
antibodi
present
necessarili
provid
protect
infect
hcov
may
reduc
number
clinic
evalu
infect
sever
pcr
posit
hcov
nucleic
acid
minor
ri
studi
antibodi
may
reduc
viru
shed
detect
respiratori
secret
acut
ill
time
specimen
collect
onset
ri
could
affect
pcr
posit
rate
well
seroconvers
threshold
bind
antibodi
titer
threefold
associ
acut
ri
inconsist
predictor
concomit
fourfold
neutral
antibodi
chang
chang
bind
antibodi
statist
better
antibodi
gmt
hcov
strain
increas
statist
compar
acut
convalesc
sera
calcul
valu
ill
gmt
calcul
evid
antibodi
respons
least
relat
strain
alphacoronavirus
vs
betacoronavirus
choos
calcul
separ
gmt
subset
sera
threefold
chang
one
hcov
strain
would
assur
signific
rise
gmt
strain
threefold
bind
antibodi
chang
fewer
number
hcov
infect
report
ri
overal
older
patient
could
consist
higher
antibodi
level
immun
mechan
protect
compar
younger
patient
enrol
bind
antibodi
titer
higher
group
group
subject
howev
actual
proport
ri
associ
hcov
serolog
chang
pcr
differ
compar
two
group
total
ri
group
assess
associ
hcov
infect
compar
ill
group
known
might
constitut
protect
antibodi
level
hcov
infect
concomit
increas
bind
antibodi
one
viral
strain
like
due
stimul
antibodi
conserv
antigen
express
current
infect
strain
hcov
due
recal
immun
memori
strain
previous
infect
person
earlier
life
concomit
infect
one
strain
hcov
ri
would
unlik
repeat
infect
hcov
may
partial
explain
natur
infect
adult
patient
stimul
bind
antibodi
commonli
function
neutral
antibodi
nonneutr
antibodi
known
bind
viral
protein
n
protein
stimul
antibodi
protein
epitop
could
explan
low
correl
stimul
bind
antibodi
neutral
antibodi
sinc
neutral
antibodi
direct
protein
light
method
viru
inactiv
use
preserv
viral
antigen
determin
viral
protein
bind
antibodi
direct
orient
viral
antigen
coat
elisa
microtit
plate
may
affect
epitop
expos
avail
antibodi
bind
also
possibl
bind
antibodi
may
enhanc
infect
protect
reinfect
enhanc
felin
infecti
periton
viru
member
coronaviru
genu
antigen
relat
infect
report
mediat
antibodi
protein
epitop
also
studi
protein
sequenc
neutral
antigen
suggest
serum
antibodi
neutral
clinic
hcov
isol
may
well
laboratori
strain
hcov
use
neutral
assay
affect
sensit
neutral
assay
employ
inde
detect
respiratori
secret
patient
mutat
peak
region
spike
protein
could
lead
differ
antigen
lower
neutral
antibodi
level
respons
rate
strain
older
group
subject
higher
level
bind
neutral
antibodi
acut
ri
younger
subject
group
probabl
due
previou
infect
hcov
strain
longer
bind
antibodi
detect
elisa
util
inactiv
whole
virus
like
direct
hcov
protein
protein
compar
neutral
antibodi
direct
epitop
protein
method
viru
inactiv
use
may
preserv
integr
virion
antigen
confirm
bind
antibodi
detect
elisa
direct
protein
antigen
bind
antibodi
recombin
n
protein
could
measur
case
posit
statist
correl
bind
antibodi
level
acut
convalesc
sera
within
hcov
genera
appear
closer
correl
bind
antibodi
neutral
antibodi
convalesc
sera
acut
ill
sera
particularli
respect
closer
bind
antibodi
correl
strain
within
alphacoronaviru
strain
within
betacoronaviru
genera
preexist
serolog
statu
variou
strain
coronaviru
among
patient
undergo
acut
infect
seriou
current
outbreak
viru
immun
respons
infect
known
patient
infect
seroneg
onset
ill
develop
bind
potenti
protect
neutral
antibodi
correl
convalesc
sera
delay
serolog
respons
occur
sever
ill
higher
viral
shed
contradistinct
subject
alreadi
seroposit
four
strain
onset
ri
increas
bind
antibodi
bracket
ri
signal
like
intercurr
hcov
infect
frequent
increas
neutral
antibodi
viral
nucleic
acid
detect
respiratori
secret
frequent
young
compar
older
adult
correl
bind
neutral
antibodi
homolog
relat
hcov
strain
though
statist
signific
comparison
unlik
simultan
infect
one
strain
hcov
concomit
increas
bind
neutral
antibodi
one
strain
consist
stimul
antibodi
recal
immun
memori
suscept
repeat
infect
hcov
may
explain
part
stimul
neutral
antibodi
minor
ri
increas
bind
antibodi
sinc
bind
antibodi
increas
commonli
neutral
antibodi
may
sensit
seroepidemiolog
tool
neutral
antibodi
identifi
ri
due
common
hcov
strain
author
declar
conflict
interest
